全文获取类型
收费全文 | 30621篇 |
免费 | 2150篇 |
国内免费 | 110篇 |
专业分类
耳鼻咽喉 | 319篇 |
儿科学 | 826篇 |
妇产科学 | 539篇 |
基础医学 | 4588篇 |
口腔科学 | 693篇 |
临床医学 | 3114篇 |
内科学 | 6464篇 |
皮肤病学 | 452篇 |
神经病学 | 2803篇 |
特种医学 | 1101篇 |
外国民族医学 | 1篇 |
外科学 | 4492篇 |
综合类 | 174篇 |
一般理论 | 45篇 |
预防医学 | 2286篇 |
眼科学 | 530篇 |
药学 | 2396篇 |
中国医学 | 31篇 |
肿瘤学 | 2027篇 |
出版年
2023年 | 178篇 |
2022年 | 295篇 |
2021年 | 622篇 |
2020年 | 484篇 |
2019年 | 674篇 |
2018年 | 730篇 |
2017年 | 594篇 |
2016年 | 755篇 |
2015年 | 711篇 |
2014年 | 1030篇 |
2013年 | 1391篇 |
2012年 | 1931篇 |
2011年 | 1898篇 |
2010年 | 1073篇 |
2009年 | 1009篇 |
2008年 | 1609篇 |
2007年 | 1716篇 |
2006年 | 1575篇 |
2005年 | 1522篇 |
2004年 | 1487篇 |
2003年 | 1253篇 |
2002年 | 1276篇 |
2001年 | 549篇 |
2000年 | 541篇 |
1999年 | 530篇 |
1998年 | 326篇 |
1997年 | 284篇 |
1996年 | 286篇 |
1995年 | 240篇 |
1994年 | 242篇 |
1993年 | 227篇 |
1992年 | 382篇 |
1991年 | 398篇 |
1990年 | 396篇 |
1989年 | 396篇 |
1988年 | 308篇 |
1987年 | 325篇 |
1986年 | 290篇 |
1985年 | 346篇 |
1984年 | 245篇 |
1983年 | 225篇 |
1982年 | 192篇 |
1981年 | 170篇 |
1980年 | 154篇 |
1979年 | 196篇 |
1978年 | 161篇 |
1977年 | 149篇 |
1975年 | 127篇 |
1974年 | 153篇 |
1973年 | 130篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
Maria Skaalum Petersen Marin Strm Jgvan Pll Fjallsbak Jhanna Ljs Hansen Slrun Larsen Eina H. Eliasen Malan Johansen Anna Sofía Veyhe Marnar Fríheim Kristiansen Pl Weihe 《Emerging infectious diseases》2022,28(1):242
We conducted a second nationwide severe acute respiratory syndrome coronavirus 2 seroprevalence study in the Faroe Islands during November 2020. We found crude seroprevalence was 0.3% and prevalence was 0.4% after adjusting for test sensitivity and specificity. This low seroprevalence supports the prevention strategies used in the Faroe Islands. 相似文献
992.
993.
994.
995.
996.
Clinical Epileptology - Die Autoimmunenzephalitis (AE) ist durch eine variable neuropsychiatrische Symptomatologie gekennzeichnet. Eine frühe Diagnosestellung ist hilfreich, um die Prognose... 相似文献
997.
998.
Katrina Hueniken MPH Catriona M. Douglas BSc MBChB MD Ashok R. Jethwa MD Maryam Mirshams MSc Lawson Eng MD Andrew Hope MD Douglas B. Chepeha MD David P. Goldstein MD MSc Jolie Ringash MD MSc Aaron Hansen BSc MBBS Rosemary Martino PhD Madeline Li MD PhD Geoffrey Liu MD Wei Xu MD John R. de Almeida MD MSc 《Cancer》2020,126(17):4042-4050
999.
Sarina A. Piha-Paul Do-Youn Oh Makoto Ueno David Malka Hyun Cheol Chung Adnan Nagrial Robin K. Kelley Willeke Ros Antoine Italiano Kazuhiko Nakagawa Hope S. Rugo Filippo de Braud Andrea Iolanda Varga Aaron Hansen Hui Wang Suba Krishnan Kevin G. Norwood Toshihiko Doi 《International journal of cancer. Journal international du cancer》2020,147(8):2190-2198
We present data from patients with advanced biliary tract cancer (BTC) receiving pembrolizumab in the KEYNOTE-158 (NCT02628067; phase 2) and KEYNOTE-028 (NCT02054806; phase 1b) studies. Eligible patients aged ≥18 years from both studies had histologically/cytologically confirmed incurable BTC that progressed after standard treatment regimen(s), measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, Eastern Cooperative Oncology Group performance status 0/1, and no prior immunotherapy. Programmed death ligand 1 (PD-L1)-positive tumors were required for eligibility in KEYNOTE-028 only. Patients received pembrolizumab 200 mg every three weeks (KEYNOTE-158) or 10 mg/kg every two weeks (KEYNOTE-028) for ≤2 years. Primary efficacy endpoint was objective response rate (ORR) by RECIST v1.1. Response assessed by independent central review is reported. KEYNOTE-158 enrolled 104 patients and KEYNOTE-028 enrolled 24 patients. Median (range) follow-up was 7.5 months (0.6-34.3) in KEYNOTE-158 and 5.7 months (0.6-55.4) in KEYNOTE-028. In KEYNOTE-158, ORR was 5.8% (6/104; 95% CI, 2.1%-12.1%); median duration of response (DOR) was not reached (NR) (range, 6.2-26.6+ months). Median (95% CI) OS and PFS were 7.4 (5.5-9.6) and 2.0 (1.9-2.1) months. Among PD-L1-expressers (n = 61) and PD-L1-nonexpressers (n = 34), respectively, ORR was 6.6% (4/61) and 2.9% (1/34). In KEYNOTE-028, ORR was 13.0% (3/23; 95% CI, 2.8%-33.6%); median DOR was NR (range, 21.5-53.2+ months). Median (95% CI) OS and PFS were 5.7 (3.1-9.8) and 1.8 (1.4-3.1) months. Grade 3 to 5 treatment-related adverse events occurred in 13.5% of patients in KEYNOTE-158 (no grade 4; grade 5 renal failure, n = 1) and 16.7% in KEYNOTE-028 (no grade 4/5). In summary, pembrolizumab provides durable antitumor activity in 6% to 13% of patients with advanced BTC, regardless of PD-L1 expression, and has manageable toxicity. 相似文献
1000.
James R. Barrett MD Victoria Rendell MD Courtney Pokrzywa MD Alexandra G. Lopez-Aguiar MD John Cannon BA George A. Poultsides MD MS Flavio Rocha MD Angelena Crown MD Eliza Beal MD Timothy Michael Pawlik MD MPH PhD Ryan Fields MD Roheena Z. Panni MD MPHS Paula Smith MD Kamran Idrees MD Clifford Cho MD Megan Beems MD Shishir Maithel MD Sharon Weber MD Daniel Erik Abbott MD 《Journal of surgical oncology》2020,121(7):1067-1073